Antimicrobial susceptibilities of *Clostridium difficile*

R SHUTTLEWORTH, MILDRED TAYLOR, AND DM JONES

*From the Public Health Laboratory, Withington Hospital, Manchester M20 8LR, UK*

SUMMARY The antimicrobial susceptibilities of 78 strains of *Clostridium difficile* isolated from patients with and without gastrointestinal symptoms were determined and compared. Strains from patients with symptoms were more likely to show resistance to antibiotics. The antimicrobial susceptibilities of toxigenic and non-toxigenic strains were found to be similar.

In the last two years advances have been made in understanding the aetiology of pseudomembranous colitis. Larson and Price\(^1\) and Rifkin *et al.*\(^2\) demonstrated a toxin in the faeces of patients with PMC that was shown to be neutralised by *Clostridium sordellii* antitoxin and produced by *Clostridium difficile*.\(^3\) More evidence has accumulated\(^4\)\(^5\) that suggests that *C. difficile* is associated with antibiotic-associated PMC. This condition has been described in patients who have received treatment with an antibiotic from most of the major groups of antibiotics except vancomycin and metronidazole. The presence of the toxin of *C. difficile* in faeces has also been associated with diarrhoea related to antibiotic therapy, but without the pathological features of PMC. It is thought that the antibiotic therapy produces changes in the faecal flora and allows *C. difficile* to proliferate and produce pathological amounts of toxin. It is therefore of interest to establish the antibiotic sensitivity patterns of *C. difficile* isolated from the faeces of normal individuals.

All strains of *C. difficile* isolated from patients with PMC have been found to be highly sensitive to vancomycin.\(^6\)\(^7\) and vancomycin has been used with success in the treatment of PMC,\(^8\)\(^9\) though relapse has been observed after cessation of therapy.\(^10\) Published reports\(^6\)\(^7\) on the antibiotic susceptibility of *C. difficile* have given data on only a few strains, and these have been collected mainly from proven cases of PMC. This report gives data on a total of 78 strains, including those isolated from patients without gastrointestinal symptoms. A comparison has been made of the sensitivity patterns of both toxigenic and non-toxigenic strains, and the susceptibilities of strains isolated from asymptomatic carriers have been compared with those from patients with gastrointestinal symptoms.

**Material and methods**

**SOURCE OF STRAINS**

Seventy-two strains of *C. difficile* were isolated from the faeces of patients with PMC or antibiotic-associated diarrhoea and from faeces of patients without gastrointestinal symptoms (Table 1). Not all patients with symptoms were subjected to sigmoidoscopy so we have regarded patients with PMC or antibiotic-associated diarrhoea as a single group. In addition, strains 17249, 7988, 32288, 13231, 25917, and 21153 were supplied by Dr DW Burdon, of Birmingham; all six were toxigenic strains isolated from adults with PMC. The organisms were identified on the grounds of colonial and cellular morphology, biochemical reactions, and gas-liquid chromatography.\(^11\)

<table>
<thead>
<tr>
<th>Patient category</th>
<th>Toxigenic</th>
<th>Non-toxigenic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomless babies 0-2 years</td>
<td>29</td>
<td>31</td>
</tr>
<tr>
<td>Symptomless adults</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Symptomatic adults, Manchester</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>Symptomatic adults, Birmingham</td>
<td>6</td>
<td>0</td>
</tr>
</tbody>
</table>

**TOXIGENICITY TESTING**

Cultures of *C. difficile* were grown in cooked meat medium for two days at 37°C, and culture supernatants were tested for cytopathogenicity to MRC 5 cells and neutralisation by *C. sordellii* antitoxin.\(^1\) During the course of toxigenicity testing it was found that some strains failed to show a cytopathic effect. In order to confirm the absence of toxigenicity, one such strain was subjected to further testing. The

Received for publication 10 March 1980
Antimicrobial susceptibilities of Clostridium difficile

organism was grown in a medium containing 2% Proteose Peptone No. 3 (Difco) and 1% glucose, and duplicate cultures were incubated at 37°C and 42°C for three days before being tested for cytotoxicity in tissue culture, as described above, with negative results. The same strain was then cultured for two days in Brain-Heart Infusion broth (Oxoid) at 37°C, and 0.5 ml of the culture supernatant was injected subcutaneously into a guinea-pig, as described by Hall and O'Toole.12 The guinea-pig failed to show any signs of toxemia. This strain and eight other 'non-toxigenic' strains were grown in 2% Proteose Peptone No. 3 (Difco) containing 0.5% glucose and 1 µg/ml clindamycin for three days and retested for toxin production in tissue culture. The presence of this concentration of clindamycin did not stimulate these strains to produce toxin. Subsequently, strains that failed to show a cytotoxic effect were regarded as non-toxigenic.

DETERMINATION OF MINIMUM INHIBITORY CONCENTRATIONS (MIC)

All strains were tested against the following antibiotics by the agar dilution method: ampicillin, cefoxitin, cephalexin, clindamycin, metronidazole, erythromycin, sulphadiazine, tetracycline, and vancomycin. The antibiotics were incorporated in doubling dilutions in 20 ml DST agar plates containing 10% lysed horse blood, giving final concentrations ranging from 0.125 to 1024 µg/ml. Suspensions of Cl. difficile from overnight cultures on blood agar were made in nutrient broth and applied to the agar surface using a multipoint inoculator. The inoculum was of the order of 10^4 colony-forming units. All plates were incubated anaerobically for 48 hours at 37°C using the Gas Pak system (Becton Dickinson Ltd).

DISC SENSITIVITY TESTS

Disc sensitivity tests were performed on Oxoid DST agar containing 10% lysed horse blood incubated at 37°C under anaerobic conditions. Results were recorded after 18-24 hours' incubation. The following antibiotic discs were used: tetracycline (10 ug), erythromycin (5 µg), clindamycin (2 µg), ampicillin (10 µg), cephradine (30 µg), cotrimoxazole (25 µg), chloramphenicol (30 µg), vancomycin (5 µg), metronidazole (5 µg), fucidin (10 µg), colistin (10 µg), gentamicin (10 µg), novobiocin (5 µg), spectinomycin (25 µg), trimethoprim (1 µg), and nalidixic acid (30 µg).

Results

MINIMUM INHIBITORY CONCENTRATIONS

The results of MIC determinations are given in

Table 2 Minimum inhibitory concentrations for various antibiotics (78 strains)

<table>
<thead>
<tr>
<th>Group*</th>
<th>Antibiotic</th>
<th>No. of strains with MIC (µg/ml) of:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&lt;0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 &gt;1024</td>
</tr>
<tr>
<td>I</td>
<td>Cefoxitin</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Cephalixin</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Vancomycin</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Erythromycin</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Ampicillin</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Clindamycin</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Tetracycline</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Metronidazole</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Sulphadiazine</td>
<td></td>
</tr>
</tbody>
</table>

*Group I 29 toxigenic strains of Cl. difficile from babies aged 0-2 years.
II 32 non-toxigenic strains of Cl. difficile (31 from babies aged 0-2 years and 1 from a symptomless adult).
III 17 strains of Cl. difficile from adults with gastrointestinal symptoms (including 1 non-toxigenic strain).
Table 3 Antibiotic susceptibilities of strains from patients with gastrointestinal symptoms

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Previous antibiotic treatment</th>
<th>Sensitivity pattern</th>
</tr>
</thead>
<tbody>
<tr>
<td>M1*</td>
<td>None</td>
<td>Resistant to erythromycin, clindamycin†</td>
</tr>
<tr>
<td>M2</td>
<td>Cotrimoxazole</td>
<td>Resistant to tetracycline, cotrimoxazole</td>
</tr>
<tr>
<td>M3</td>
<td>Ampicillin, fluocoxacillin</td>
<td>Typical‡</td>
</tr>
<tr>
<td>M4</td>
<td>Ampicillin</td>
<td>Typical</td>
</tr>
<tr>
<td>M5</td>
<td>Clindamycin</td>
<td>Resistant to tetracycline, erythromycin, clindamycin</td>
</tr>
<tr>
<td>M6</td>
<td>Gentamicin, fluocoxacillin</td>
<td>Typical</td>
</tr>
<tr>
<td>M7</td>
<td>Cotrimoxazole, fluocoxacillin, gentamicin, carbenicillin</td>
<td>Typical</td>
</tr>
<tr>
<td>M8</td>
<td>Cephalaxin</td>
<td>Typical</td>
</tr>
<tr>
<td>M9</td>
<td>Cephadrine, gentamicin, ampicillin</td>
<td>Typical</td>
</tr>
<tr>
<td>M10</td>
<td>Ampicillin, metronidazole, cotrimoxazole</td>
<td>Resistant to tetracycline, erythromycin, clindamycin</td>
</tr>
<tr>
<td>M11</td>
<td>Clindamycin</td>
<td>Typical</td>
</tr>
<tr>
<td>B1</td>
<td>Not known</td>
<td>Typical</td>
</tr>
<tr>
<td>B2</td>
<td>Not known</td>
<td>Typical</td>
</tr>
<tr>
<td>B3</td>
<td>Not known</td>
<td>Typical</td>
</tr>
<tr>
<td>B4</td>
<td>Not known</td>
<td>Typical</td>
</tr>
<tr>
<td>B5</td>
<td>Not known</td>
<td>Typical</td>
</tr>
<tr>
<td>B6</td>
<td>Not known</td>
<td>Typical</td>
</tr>
</tbody>
</table>

*M = Manchester; B = Birmingham.
†Typical = resistant to cephalexin, cefoxitin, gentamicin; moderately resistant to clindamycin; and sensitive to tetracycline, erythromycin, cotrimoxazole.
‡Typical = resistant to clindamycin.

Table 3. The MIC results were in accord with the disc sensitivity results except for cephalexin, cefoxitin, and ampicillin. All strains were resistant (MIC 32-256 μg/ml) to both cephalexin and cefoxitin, and the MIC of ampicillin varied between 1 and 8 μg/ml. All strains were sensitive to metronidazole (MIC 0.125-4 μg/ml) and vancomycin (MIC 1-4 μg/ml). The susceptibilities of the strains isolated from patients with symptoms were compared to previous antibiotic therapy (Table 3).

DISC SENSITIVITY TESTS

Disc sensitivity tests correlated well with the MIC results for the antibiotics given in Table 2. In addition, all strains gave zones greater than 20 mm with fucidin, and no zones were developed against colistin, gentamicin, novobiocin, spectinomycin, trimethoprim, or nalidixic acid. Two strains showed smaller than average zones with chloramphenicol; both were from cases of PMC and both were from Birmingham.

Discussion

It is not clear from published work whether the strains associated with gastrointestinal symptoms differ in their antibiotic susceptibilities from those of strains isolated from symptomless excreters. All the strains of Cl. difficile that we examined were resistant to cephalexin and cefoxitin. Resistance to clindamycin, tetracycline, erythromycin, or cotrimoxazole was observed but was restricted to strains isolated from patients with gastrointestinal symptoms. It may be that the use of any of these agents could be associated with the proliferation of Cl. difficile in the gut. There were no common combinations of antibiotic resistance among the strains isolated from patients with symptoms although, as shown in Table 3, many were resistant to an antibiotic previously taken by the patient. For the majority of strains, the MIC of clindamycin was 1-8 μg/ml, but those strains that showed no zones on disc testing were much more resistant (MIC >1024 μg/ml), and all of these came from patients with gastrointestinal symptoms. All the strains of Cl. difficile were uniformly sensitive to vancomycin, confirming the conclusions of Burdon et al.† that this drug may be expected to produce good results for the treatment of PMC. There was no correlation between the production of toxin and resistance to antibiotics since the patterns for toxigenic and non-toxigenic strains from symptomless excreters were generally similar. Indeed, five asymptomatic patients yielded both toxigenic and non-toxigenic strains, and when the susceptibilities of these pairs of strains were compared there were no significant differences.

This investigation was supported by a grant from the North West Regional Health Authority.

References

**Antimicrobial susceptibilities of Clostridium difficile**


Requests for reprints to: Dr DM Jones, Public Health Laboratory, Withington Hospital, Manchester M20 8LR, UK.

---

**Reports and Bulletins prepared by the Association of Clinical Biochemists**

The following reports and bulletins are published by the Association of Clinical Biochemists. They may be obtained from The Publishing Department, British Medical Journal (ACB Technical Bulletins), BMA House, Tavistock Square, London WC1H 9JR. Overseas readers should remit by British Postal or Money Order.

**SCIENTIFIC REVIEWS** (price £1.00/$2.00 each)

1. The assessment of thyroid function March 1971 FV FLYNN and JR HOBBS

2. Renal function tests suitable for clinical practice January 1972 FL MITCHELL, N VEALL, and RWE WATTS

3. Biochemical tests for the assessment of fetoplacental function May 1975 CE WILDE and RE OAKLEY

4. Test of exocrine pancreatic function March 1977 AH GOWENLOCK

5. Assay of cholinesterase in clinical chemistry March 1979 ELSIE SILK, J KING, and MARY WHITTAKE

**TECHNICAL BULLETINS** (price £1.00/$2.00 each)

22. Bilirubin standards and the determination of bilirubin by manual and technicon AutoAnalyzer methods January 1971 BARBARA BILLING, RUTH HASLAM, and N WALD

23. Interchangeable cells for spectrophotometers and fluorimeters September 1971 SS BROWN and AH GOWENLOCK

24. Simple tests to detect poisons March 1972 BW MEADE et al.

25. Blood gas analysers May 1972 K DIXON

26. Kits for enzyme activity determination September 1972 SB ROSALKI and D TARLOW

27. Assessment of pumps suitable for incorporation into existing continuous flow analytical systems November 1972 A FLECK et al.


29. Control materials for clinical biochemistry (5th edition) September 1973 JF STEVENS


31. Determination of uric acid in blood and in urine July 1974 RWE WATTS

32. A survey of amino acid analysers readily available in the United Kingdom September 1974 JE CARLYLE and P PURKISS

33. Definitions of some words and terms used in automated analysis November 1974 A FLECK, R ROBINSON, SS BROWN, and JR HOBBS

34. Measurement of albumin in the sera of patients January 1975 LINDA SLATER, PM CARTER, and JR HOBBS

35. Investigation of the validity of temperature correction factors for serum aspartate and alanine transaminases March 1975 SB ROSALKI et al.

36. Factors influencing the assay of creatinine November 1975 JGH COOK

37. A survey of enzyme reaction rate analysers readily available in the United Kingdom July 1977 RA SAUNDERS and RF BURNS

38. Transport of specimens for clinical chemistry analysis November 1977 P WILDING, JF ZILVA, and CE WILDE

39. A scheme for the evaluation of diagnostic kits May 1978 PH LLOYD

40. A practical guide to gamma-counting in radioimmunoassay January 1980 CE WILDE and D OTTEWELL
Antimicrobial susceptibilities of Clostridium difficile.

R Shuttleworth, M Taylor and D M Jones

doi: 10.1136/jcp.33.10.1002

Updated information and services can be found at:
http://jcp.bmj.com/content/33/10/1002

Email alerting service

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/